BiotechTube

Pemetrexed + Carboplatin

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Small Cell Lung Carcinoma

Conditions

Non Small Cell Lung Carcinoma

Trial Timeline

Apr 1, 2008 → Dec 1, 2012

NCT ID
NCT01836575

About Pemetrexed + Carboplatin

Pemetrexed + Carboplatin is a phase 3 stage product being developed by Eli Lilly for Non Small Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01836575. Target conditions include Non Small Cell Lung Carcinoma.

What happened to similar drugs?

20 of 20 similar drugs in Non Small Cell Lung Carcinoma were approved

Approved (20) Terminated (2) Active (0)
✅mouse nerve growth factorSun PharmaceuticalApproved
✅Pemetrexed + CarboplatinEli LillyApproved
✅pemetrexedEli LillyApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅OsimertinibAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT01020786ApprovedCompleted
NCT00906282Phase 2Completed
NCT01836575Phase 3Completed
NCT00494026Phase 2Terminated
NCT00383266Phase 2Terminated
NCT00350792Phase 2Completed
NCT00072865Phase 2Completed

Competing Products

20 competing products in Non Small Cell Lung Carcinoma

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
LY3295668 ErbumineEli LillyPhase 1
29
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
TNG456 + abemaciclibEli LillyPhase 1/2
39
pemetrexed + cisplatinEli LillyPhase 1/2
24